company background image
AMED logo

Amedisys NasdaqGS:AMED Stock Report

Last Price

US$84.47

Market Cap

US$2.8b

7D

-1.4%

1Y

-11.5%

Updated

22 Dec, 2024

Data

Company Financials +

My Notes

Capture your thoughts, links and company narrative

Amedisys, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Amedisys
Historical stock prices
Current Share PriceUS$84.47
52 Week HighUS$98.95
52 Week LowUS$82.15
Beta0.73
1 Month Change-6.81%
3 Month Change-12.80%
1 Year Change-11.54%
3 Year Change-47.70%
5 Year Change-49.07%
Change since IPO1,508.95%

Recent News & Updates

Final Push For Amedisys As UnitedHealth Awaits Regulatory Clearance

Nov 05

Recent updates

Final Push For Amedisys As UnitedHealth Awaits Regulatory Clearance

Nov 05

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Apr 10
Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Feb 25
Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

Feb 10
Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Jan 03
At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Dec 16
A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Nov 12
Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

Sep 19
Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Sep 04
An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Amedisys: ROIC, Tangible Book Value Each Softening

Aug 24

Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Aug 04
Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates

Jul 27

We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

Jul 20
We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Jun 04
At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

May 05
Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Apr 20
Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Apr 06
Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Is Amedisys (NASDAQ:AMED) A Risky Investment?

Feb 20
Is Amedisys (NASDAQ:AMED) A Risky Investment?

Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

Jan 19
Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

Dec 03
Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

Nov 18
These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

Aug 18
Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Jul 23
Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Amedisys: Strategic Contessa Acquisition Underpins The Home Healthcare Growth Opportunity

Jul 18

Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive

Jun 28
Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive

It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Jun 02
It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

May 24
Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

Shareholder Returns

AMEDUS HealthcareUS Market
7D-1.4%-4.1%-2.4%
1Y-11.5%-10.2%23.4%

Return vs Industry: AMED underperformed the US Healthcare industry which returned -10.2% over the past year.

Return vs Market: AMED underperformed the US Market which returned 23.3% over the past year.

Price Volatility

Is AMED's price volatile compared to industry and market?
AMED volatility
AMED Average Weekly Movement2.3%
Healthcare Industry Average Movement7.6%
Market Average Movement6.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: AMED has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: AMED's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198219,000Richard Ashworthwww.amedisys.com

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Amedisys, Inc. Fundamentals Summary

How do Amedisys's earnings and revenue compare to its market cap?
AMED fundamental statistics
Market capUS$2.77b
Earnings (TTM)US$82.93m
Revenue (TTM)US$2.32b

33.4x

P/E Ratio

1.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AMED income statement (TTM)
RevenueUS$2.32b
Cost of RevenueUS$1.31b
Gross ProfitUS$1.01b
Other ExpensesUS$930.68m
EarningsUS$82.93m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)2.53
Gross Margin43.67%
Net Profit Margin3.57%
Debt/Equity Ratio29.4%

How did AMED perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:58
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amedisys, Inc. is covered by 32 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian HoffmanAvondale Partners
Matthew GillmorBaird
Steven ValiquetteBarclays